Venture capital firm Edmond de Rothschild Investment Partners led the B round as a new investor, alongside InnoBio and Omnes Capital, the former venture unit of local bank Credit Agricole.

Venture capital firms Prolog Ventures and Holton Capital Group have provided funds to launch Sequoia Vaccines, a spin-out tackling urinary-tract infections from drug-discovery company Sequoia Sciences.

In September 2011, Crescendo raised $31m in its C round with a further $25m in venture debt and buyout option provided by strategic investor Myriad Genetics.

Brian Bischoff, chief executive of Healthsense, said: "The addition of respected investors and industry leaders like Merck GHIF [Global Health Innovation Fund] and Fallon Community Health Plan supports our belief that our technology and approach can both improve quality and reduce cost."

The $12m second tranche is for a human study of a stapled peptide.

Opko gained a worldwide license from BioZone to develop and commercialize QuSomes, a skin care product, and an enhanced formulation of Propofol, which is used for anesthesia and sedation.